Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 1,600 shares, a growth of 1,500.0% from the September 15th total of 100 shares. Based on an average daily trading volume, of 11,000 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 11,000 shares, the days-to-cover ratio is presently 0.1 days.
Hypermarcas Price Performance
HYPMY traded down $0.07 during midday trading on Thursday, reaching $3.82. 5,939 shares of the company's stock were exchanged, compared to its average volume of 61,429. The business's 50-day moving average price is $4.23 and its 200 day moving average price is $4.27. The stock has a market capitalization of $2.42 billion, a PE ratio of 18.17 and a beta of 0.83. Hypermarcas has a 1-year low of $2.64 and a 1-year high of $5.12. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share (EPS) for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.
Wall Street Analysts Forecast Growth
Separately, Scotiabank raised shares of Hypermarcas to a "strong-buy" rating in a report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Strong Buy".
Check Out Our Latest Research Report on Hypermarcas
About Hypermarcas
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.